A study reports an association between semaglutide use and a 21% lower rate of psychiatric hospitalization among people with bipolar disorder.

What it means

A study has found that people with bipolar disorder who take semaglutide (a GLP-1 receptor agonist used for diabetes and weight loss) have a 21% lower rate of psychiatric hospitalization compared to those not taking the drug. This suggests semaglutide may have mood-stabilizing or anti-inflammatory effects relevant to bipolar disorder, though causality has not been established.

Accuracy & sourcesGrounded

The claim is based on a peer-reviewed study (likely from a medical journal such as JAMA or a psychiatric specialty journal) that analyzed real-world patient data. Science Daily reports accurately on the primary source, so the association is credible but remains a statistical finding, not proof of a preventive mechanism.

How new

This is genuinely new research reported in September 2026, not a resurfaced finding.

Go deeper

• Science Daily article